Advanced financial modeling for healthcare and biotech companies. Model clinical trials, regulatory pathways, and drug development economics.
Series B healthcare and biotech companies are typically advancing through clinical trials or scaling commercial operations, raising $25-100M+ to fund expensive clinical development, regulatory submissions, and market expansion. Financial models must account for long development cycles and high regulatory risks.
| Metric | Formula | Benchmark |
|---|---|---|
| Product Sales Revenue | Units Sold × Average Selling Price | $50-500M peak sales potential |
| Licensing Revenue | Upfront + Milestone + Royalty Payments | $10-100M+ licensing deals |
| Subscription Revenue (SaaS) | Healthcare Providers × Monthly Fee | $500-5,000/month per provider |
| Clinical Trial Services | CRO Revenue + Data Analytics Services | $1-10M per trial |
| Government Contracts | Contract Value × Probability of Award | $5-50M+ government deals |
| Metric | Formula | Benchmark |
|---|---|---|
| Phase I Trial Cost | Patient Enrollment × Cost per Patient + Fixed Costs | $2-15M per trial |
| Phase II Trial Cost | Patient Enrollment × Cost per Patient + Infrastructure | $10-50M per trial |
| Phase III Trial Cost | Multi-site Enrollment × Extended Timeline Costs | $50-300M per trial |
| Regulatory Filing Costs | FDA/EMA Fees + Preparation + Consulting | $5-20M per submission |
| Manufacturing Scale-up | Facility + Equipment + Validation Costs | $20-100M+ for biologics |
| Metric | Formula | Benchmark |
|---|---|---|
| Pipeline Value | Σ(Program NPV × Probability of Success) | $500M-5B+ pipeline value |
| Clinical Milestone Achievement | Completed Milestones ÷ Planned Milestones | 75-90% milestone success |
| Partnership Deal Value | Strategic Partnerships × Average Deal Size | $50-500M+ partnerships |
| IP Portfolio Value | Patent Portfolio × Market Application | $10-100M+ IP value |
| Regulatory Success Rate | Approved Programs ÷ Submitted Programs | 60-80% approval rate |
Model Phase II trials at $10-50M and Phase III at $50-300M based on patient enrollment, trial duration, and therapeutic area. Include site management, data collection, regulatory affairs, and 20-30% contingency for timeline extensions. Factor in parallel development programs and regulatory feedback incorporation.
Use industry-standard success rates: Phase I (63%), Phase II (31%), Phase III (58%), FDA submission (85%). Apply risk-adjusted NPV calculations with 10-15% discount rates. Adjust probabilities based on your specific therapeutic area, previous trial results, and competitive landscape.
Structure deals with upfront payments ($10-100M+), development milestones ($5-50M each), regulatory milestones ($10-100M), and royalties (5-15% of net sales). Model probability-adjusted milestone payments and include co-development cost sharing arrangements.
Budget 10-20% of total development costs for regulatory affairs including FDA/EMA fees ($2-5M per submission), regulatory consulting, quality systems, and compliance staff. Include ongoing pharmacovigilance and post-market requirements for commercial products.
Model manufacturing costs as 15-40% of revenue depending on product complexity. Include facility investments ($20-100M+ for biologics), technology transfer costs, and supply chain redundancy. Plan for multiple manufacturing partners and geographic distribution requirements.
Model market access taking 1-3 years post-approval with 60-90% coverage rates. Include health economics studies ($1-5M), payer negotiations, and patient access programs. Factor in international price referencing and healthcare policy changes affecting reimbursement.
Use our comprehensive healthcare calculator to create detailed clinical development and commercialization projections for your Series B fundraising.